Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07600450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Sep 22, 2026 → May 20, 2027
See other at-risk trials from GlaxoSmithKline

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 22, 2026 to May 20, 2027 Show 4 more changesShow less
    • Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of May 15, 2026 to May 18, 2026
    • Eligibility criteria expanded, about 32 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
This is a first time in Asia (FTIA) study of GSK4771261 in healthy participants of Chinese, Japanese, and White/European ancestry. The study will test whether GSK4771261 is safe, well-tolerated, how it is processed in the body, and whether it triggers an immune response.
Trial Details
NCT Number NCT07600450
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Kidney Disease
Related terms Kidney Diseases
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov